UNSPSC 51313415: Betahistine dihydrochloride

This classification denotes a vasodilating agent with the molecular formula C8H12N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49K58SMZ7U, chemically known as 2-pyridineethanamine, n-methyl-, dihydrochloride but more generally known as betahistine dihydrochloride, which bears US NIH Compound Identifier 68643. The base compound, Betahistine, most often comes in base, dihydrochloride, hydrochloride, and mesylate forms.

European Medicines Agency schedules Betahistine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00772MIG. Most nations, for tariff and trade purposes, schedule betahistine dihydrochloride under HS 29333999. SMILES: CNCCC1CCCCN1.CL.CL.

UNSPSC 51313415 Betahistine dihydrochloride is a Commodity code that appears in state and local procurement records with little recent activity directly aligned to its nominal scope. The single matching recent opportunity in the dataset does not involve betahistine itself; instead, Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for naloxone and drug deactivation systems—a public health procurement unrelated to the betahistine classification. The other two recent opportunities tagged under or near this code—a Texas HHS RFI on direct-to-manufacturer prescriptions and a Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products—address pharmaceutical procurement broadly but do not target betahistine dihydrochloride specifically. State and local procurement activity under this code does not show consistent demand for betahistine as a line item; the Seminole County solicitation, while tagged with pharmaceutical codes in some systems, actually seeks naloxone, which serves a distinct therapeutic and emergency-response function.

Recent pharmaceutical procurements by state and local bodies reflect broader supply-chain and cost-management priorities. The Minnesota MMCAP RFP (due March 26, 2026) established multi-year contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with pricing competitiveness weighted at 75 percent of evaluation and mandatory cGMP and DSCSA compliance. The Texas HHS RFI (response deadline April 3, 2026) signals state interest in direct-to-manufacturer prescription models outside traditional PBM and GPO channels. Issuing bodies include state health and human services commissions, county public health departments, and cooperative purchasing consortia; no repeat buyers or standout concentration around betahistine dihydrochloride emerge from the recent record. Procurement activity appears spread across the Upper Midwest (Minnesota), South (Texas, Florida), and cooperative purchasing networks serving multiple jurisdictions. The code shows limited decision relevance for vendors focused on betahistine supply; broader pharmaceutical vendors pursuing state and local health agency contracts should monitor generic-product RFPs and cooperative purchasing vehicles rather than expect solicitations under this specific commodity classification.